In early 2025, Find Therapeutics gained international exposure through a feature in Nature Biotechnology.
Find Therapeutics is featured in the March 2025 issue of Nature Biotechnology, as part of the Canada Biotech Scene section. This issue includes a series of sponsored contributions highlighting Canadian companies active in the biopharmaceutical sector.
With this publication in a magazine of international scope, Find gains visibility among a broader audience of researchers, clinicians, and industry stakeholders involved in biotechnology and biomedical innovation.
Presented as promotional content, the article entitled “Finding a new path in multiple sclerosis treatment” outlines the scientific and clinical rationale behind FTX-101, a transmembrane peptide targeting the NRP1/Plexin-A1 receptor complex — a mechanism involved in remyelination processes.
The article summarizes the foundations of the FTX-101 development program, with a focus on its lead indication in chronic optic neuropathy (CON), a condition frequently associated with multiple sclerosis. It also presents the outlook for future clinical development of this therapeutic candidate.
FTX-101 in Action
This diagram illustrates the role of FTX-101 in inhibiting Sema3A signaling at the NRP1/PLXNA1 receptor complex. By blocking this pathway, FTX-101 promotes the migration and differentiation of oligodendrocyte progenitor cells (OPCs), thereby supporting remyelination within lesions of the central nervous system.
